outcome of t-lymphoblastic leukemia-lymphoma with hyper c-vad regimen

Background: t-cell lymphoblastic leukemia (t-all) and t-cell lymphoblastic lymphoma (t-lbl) are aggressive diseases with dismal prognoses.materials and methods: all adult patients with t-all and t-lbl who were candidates for the hyper-cvad chemotherapy protocol were included. we evaluated overall survival and progression-free survival in 46 new cases. the t-all and t-lbl's number of cases were 32 and 14, respectively.results: two- and 3-year os were 41.8% (standard error (se): 7%) and 27.8% (se: 7%), respectively. two- and 3-year pfs were 36.9% (se: 7%) and 25.3% (se: 7%), respectively. the only variable that had a significant relationship with the duration of pfs and os was allogenic sct. patients receiving allogeneic sct had longer survival time (2-year overall survival of 80% against 20%) (p˂0.001).conclusion:  these data support the concept that hyper-cvad is not an appropriate and adequate regimen. we need new targeted agents in the t-all and t-lbl induction regimen while considering allogeneic sct as a consolidation.